Washington, DC - A letter in the correspondence section of the June 24, 2004 issue of the Lancet has called for the removal of rosuvastatin (Crestor ®, AstraZeneca) from the market. "The renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback